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The  threat  of  HIV/AIDS  has  elicited  a  major  response  from  the  European 
Community. 
The Council of Ministers for Health, Development and  Research  of the Com-
munity, as well ~ny--Members-ofthe  European Parliament, have repeatedly 
devoted their attention to this issue. 
In response the European Commission has presented HIV/AIDS programmes in 
the fields of public health, research and aid to development which were rapidly 
endorsed and adopted by the European Community institutions and the coun-
tries involved. 
These programmes aim at supplementing and complementing the considerable 
efforts already made by the European Community Member States as well as the 
efforts made by the developing countries and the multilateral and bilateral donor 
agencies. 
------~---
the framework of  ro-
(i)  the collection of data (epidemiology and impact of preventive measures); 
(ii)  the  implementation of public health  measures  (prevention,  information, 
health education, social support including combating discrimination). 
The strategic priorities for HIV/AIDS action in developing countries are: 
(i)  minimizing the spread of the epidemic while preventing discrimination and 
exclusion of those at risk,  infected or ill; 
(ii)  enabling the health sector to cope with the additional burden caused by the 
HIV/AIDS epidemic, the  possible  interventions,  and  their use  in  the  im-
plementation, monitoring and evaluation of progress; 
(iii) managing and  reducing the consequences of the epidemic on social  and 
economic development; 
(iv)  increasing  scientific  understanding  of,  and  learning  on,  the  HIV/AIDS 
epidemic, the possible interventions, and their use in the implementation, 
monitoring and evaluation of progress. 
Major importance is  given to research  in Europe and  in  developing countries 
through two complementary programmes (detailed in the document). 
Up to now the European Community has already devoted more than ECU  250 
million to programmes and operational projects and it is foreseen that its effort 
will continue. 6  A world with HIV/AIDS: The European Community response 
This document aims at providing the reader with an overview of the European 
Community activities, placing them both in their political context and that of the 
broader efforts in public health, research and development. 
Examples  of specific actions  are  given  together with  a  number of practical 
indications. II - Executive summary 
The European Commission has a wide range of activities that have an impact on 
the various issues associated with the HIV/AIDS epidemic. In particular, the Euro-
pean Community has several programmes, proposed and managed by the Com-
mission and adopted by the Council of Ministers of the Community in coopera-
tion with the European Parliament, to respond to the HIV/AIDS epidemic. These 
programmes address issues better dealt with collectively than by single countries. 
The European Community's public health, research and development work aims 
to prevent the spread of the epidemic. Work towards this aim involves, among 
other activities, making information available, for example about HIV/AIDS, safe 
behaviour and risk. Second, the European Community tries to mobilize all the 
groups and structures that may be able to contribute to reducing the effects of the 
epidemic. This includes coordinating and stimulating administrative and other 
organizations such that their activities may help work in the HIV/AIDS field and 
that different groups in different places are not working at cross purposes.  Fur-
thermore, HIV/AIDS issues should be integrated into a wide variety of different 
activities. Third, the European Community is  promoting research  and  studies 
which may lead to the treatment and alleviation of suffering of people infected 
by HIV and with AIDS, and to improved protection of communities. 
The  European  Community has  some  general  principles that  apply to  all  its 
HIV/AIDS work. They include the protection of the rights of the individual, par-
ticularly of individuals with HIV/AIDS. Furthermore, the European Community 
tries to adapt its action so as to bring most effort to the communities, groups or 
regions where the need is greatest. Finally, all European Community actions in-
volve collaboration, between Member States, Member States and governments 
outside Europe and national or international non-governmental organizations. 
The European Community HIV/AIDS activities can be classified into three areas: 
public health for Europe, research, and collaboration with the developing world. 
The  key component of the European  Community action within Europe  is  the 
Europe against AIDS programme. This programme funds the establishment of 
networks and collaborative projects and studies by groups within Europe. In par-
ticular, it supports pilot projects which may identify new actions and activities 
that could be of  value throughoutthe Community. The European Community has 
also contributed to actions across its frontiers, and to the harmonization and im-
provement of regulations concerning medical devices and products that are im-
plicated in the HIV/AIDS problem. 
HIV/AIDS research  is  one of the most important components in the European 
Community biomedical research  programme. Consistent with its general role, 
the  European  Community supports  collaborative  research  between  Member 
States, and funds international centres of  excellence, or facilities which serve the 
international scientific community. 
Finally, the European  Community has  developed a programme of active col-
laboration with countries in the developing world, to help them address the pro-8  A world with HIV/AIDS: The European Community response 
blems they face and to minimize the spread of HIV/AIDS and deal with the conse-
quences ofthe epidemic. This programme has gained much experience through 
seven  years of successful  intervention which has  led to the establishment of a 
detailed framework of policy and goals for HIV/AIDS work in developing coun-
tries. One particularity of this programme is its overall view: it addresses a wide 
variety of HIV/AIDS-related  issues,  which  include health  problems and  also 
social, political and economic causes  and consequences. Thus, the HIV/AIDS 
problem is integrated both into aid for development and also the wider context 
of health in the developing world. 
These different activities will continue because HIV/AIDS is causing problems 
that society will have to learn to live with for the foreseeable future. Ill - Introduction 
The HIV/AIDS epidemic is affecting millions of people throughout the world and 
the situation will continue to deteriorate. In addition, HIV/AI OS causes extensive 
human suffering and economic and social disruption. From being unimagined, 
it became, in many countries, a significant cause of death and of economic and 
social  upheaval  within  10  years.  HIV/AIDS presents a major challenge to the 
medical and scientific community: after more than  10 years of extensive effort, 
there is no immediate prospect of a vaccine or effective therapy. Thus, the only 
measures available are preventive. However, prevention of  the transmission of  the 
virus is  proving extraordinarily difficult. 
The modes of transmission of HIV can  be grouped for convenience into four 
categories  with  very  different characteristics:  hetero  and  homosexual  inter-
course; motherto child (vertical); exposure to contaminated blood products; and 
use  of contaminated  needles  for drug injection.  To  date,  the only mode of 
transmission that has been effectively blocked is the use of contaminated blood 
and blood products. However, even  in this area, further efforts are still needed, 
particularly in the developing world. 
The incidence of HIV/AIDS is increasing worldwide. The incidence varies enor-
mously between countries and between particular populations within countries. 
For example, the incidence of HIV/AIDS is  much higher in North America and 
Africa and lower in the Middle East than in Europe. Up to the end of 1993 there 
have been more than 100000 cumulated cases of AIDS in the European Com-
munity with a very uneven distribution: more than 500 AIDS cases per million 
inhabitants in France and Spain and fewer than 100 per million in Greece. One 
must also stress that about halfofthe AIDS cases recorded in the Community have 
already  resulted  in  death.  Furthermore,  the  distribution of cases  among the 
various risk groups and the rates of increase and of transmission by the different 
modes also vary considerably between countries. As  a consequence, the pro-
blems faced by the different countries of the Community are not the same and 
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this has to be taken into account in developing Community-wide approaches; in 
addition the cultural and individual behaviours are not homogeneous, and the 
infrastructures have different attributes. 
Worldwide, it has  been  the countries  least  equipped to cope that have  been 
hardest hit. Africa has the highest incidence of HIV/AIDS, and other developing 
countries are expected to suffer the worst increases in the years to come. Thus, 
in addition to the existing serious health problems, many developing countries 
are facing the extra massive burden of the HIV/AIDS epidemic. People live a long 
time after being infected with HIV, but, because of  the nature of  the viral infection, 
may transmit the virus under certain circumstances and are susceptible to oppor-
tunistic infections. This leads to great individual suffering and in many cases to 
serious economic and social problems for both the individual affected and his 
or her immediate family and social group. Solidarity between individuals, groups 
and nations to address these problems is a moral and practical necessity. The ef-
forts ofthe European Community and its Member States in this field and the close 
collaboration between the European Community and more than 100 countries 
in the world, mainly developing countries, as well as the cooperation between 
the European Commission and international organizations active in the field of 
AIDS, are striking examples of this solidarity. Collaboration between countries 
can avoid duplication of effort, and lessons can be learned from the experience 
of others. 
The epidemic is causing an increased burden on the health-care system of many 
countries. To compound the problems, a large proportion of the people affected 
are young adults who would otherwise be economically active. It is  important 
to minimize the economic effects.  The economic argument is  unambiguous: 
prevention  pays.  Indeed, there are  areas  of the world where,  if the spread  of 
HIV/AIDS is  not contained, there is  likely to be social and economic chaos. 
'Investing in  health', The world development report (1993)  by  the World  Bank, 
states: 
'  ... spending on health can also be justified on purely economic grounds. Improv-
ed  health contributes to economic growth in four ways:  it reduces  production 
losses caused  by worker illness; it permits the use of natural resources that had 
been totally or nearly inaccessible because of disease; it increases the enrolment 
of children in school and makes them better able to learn; and it frees for alter-
native uses resources that would otherwise have to be spent on treating illness.' 
Since the  recognition of the epidemic in  North America,  it has  been  a politically 
charged subject with a high profile in  the public eye.  Modes of transmission  have 
enormous implications for both individual behaviour (notably sexual behaviour) and 
government policy. Indeed, the spread of the epidemic depends in part on the sum 
of the decisions made by  individuals concerning their behaviour, and  government 
policy and actions. Many ofthe issues of individual behaviour are for various reasons Introduction  11 
(social, cultural, political and especially because the area of sexual behaviour is 
involved) difficult for governments to address.  For these same reasons, the scale 
of  the HIV/AIDS epidemic and the associated problems take time to be recogniz-
ed  and accepted. Nevertheless, it was quickly apparent that simple denial and 
repression (of intravenous drug use or prostitution for example) would in no way 
be  able to  stem  the  progression  of the  epidemic.  For  best  effectiveness,  ap-
propriate preventive measures should be  implemented as  quickly as  possible. 
This involves the mobilization of numerous sectors.  HIV/AIDS is  both a public 
health and health-care problem, and therefore the public health and health-care 
sectors must respond. But the characteristics of the HIV/AIDS epidemic are such 
that numerous different sectors of activity are involved (human rights, education, 
free movement of individuals, aid policy, access to condoms, employment policy, 
pharmaceutical legislation, attitudes to illegal drug use  and the availability of 
clean needles, prostitution, etc.). Thus a very wide range of bodies, branches of 
government and international organizations have had to address the issues. 
This  document describes  the  ways  in  which  the  European  Community has 
responded to the HIV/AIDS epidemic. The European Community is a political 
and  administrative  organization  currently  encompassing  12  Member States. 
Decisions for joint actions or programmes and for Community-wide legislation 
are made by the Council of Ministers of the European Community and the Euro-
pean Parliament on proposals of the European Commission, which implements 
and manages the decisions. However, the role of  the European Community must 
be seen  in the framework of the concept of subsidiarity. Subsidiarity states that 
the European Community should only address issues that are better dealt with 
collectively atthe Community level than atthe level of individual Member States. 
Thus, for example, the European Community does not treat patients directly. The 
European  Commission finances  and  manages  projects which are  relevant to 
more than one Member State or are international in nature. The European Com-
munity's involvement with different HIV/AIDS issues  is  therefore variable, and 
depends in large part on whether responsibility falls to the European Community 
or its Member States. The outcome of this position is that many of the activities 
of the  European  Commission  involve coordination and  cooperation between 
governmental agencies,  non-governmental organizations and  research  institu-
tions in Member States as well as support to governments and other organizations 
in developing countries.  In  order to maximize the use of its  relatively limited 
available resources (around ECU 250 million has been committed up to now by 
the European Community to fight this epidemic), the European Commission has 
established, where appropriate, relations, and even coordinates activities with 
third countries and international organizations active in this field. The structure 
of  the European Commission is such that no one department could deal with all 
the  numerous  ramifications of the  problem.  The  European  Commission  has 
largely responded by integrating HIV/AIDS-related issues as appropriate into its 
existing structures, each of which has its own particular methods of functioning 
and  general  aims;  however  an  interdepartmental  coordination  exchange 
mechanism has  been established. IV- Public health in  Europe 
A - Europe against AIDS programme 
1.  The political context 
The Council resolution of 15 December 1988 states: 
'People with HIV or AIDS do not pose a risk to their colleagues at work ... 
A person who has  HIV but does not show pathological symptoms of AIDS 
must be treated as a normal worker fit for work.' 
The Council resolution of 22 December 1989 states: 
'(1) All discrimination against people with AIDS or HIV is a violation of  human 
rights and prevents an  effective policy of prevention. 
(2)  Free  circulation of people,  goods and  services  in the Community and 
equality of  treatment, as laid down in the EC Treaties, are guaranteed, and must 
continue to be so. 
(3) Therefore, the utmost vigilance must be exercised in the fight against all 
forms of  discrimination, in particular in hiring, atthe workplace, at school, in 
housing and in health i  nsu ranee.' 
In 1991, the Council of  Ministers for Health of the Member States, acting on a pro-
posal of the Commission, launched a major and coherent public health plan for 
the problem of HIV/AIDS. This plan was entitled 'Europe against AIDS' and was 
to run  from  1991  to 1993.  It  focused  on  actions to prevent the spread  of the 
epidemic. Evaluations early in the life of the Europe against AIDS programme 
showed that it was worth continuing and indeed generated Community added-
value. Thus further funding was supplied for the years 1994 and 1995, with only 
minor changes to the organization of the programme so as to correct certain im-
balances in the funding and to reinforce various actions. Nevertheless, this pro-
gramme is not expected to be permanent. With the new competency of  the Euro-
pean Community in the public health field, established by the Treaty on  Euro-
pean  Union, the Commission has  already identified areas where action is  ap-
propriate and the Council has concurred with the following: 
cancer; 
drug demand reduction; 
AIDS and other communicable diseases; 
health promotion, education and training; 
disease surveillance and data collection. 14  A world with HIV/AIDS: The European Community response 
Public health and the Treaty on European Union 
Article 3(o) of  the Treaty on European Union states that the activities of  the European Community 
shall  include 'a contribution to the attainment of a high level of health protection'. 
The way in which this high level of health protection is to be reached is spelled out in detail in 
Article 129. 
The Article contains four paragraphs. 
Paragraph  1 has three key ideas: 
Cooperation between Member States and support to their action 
The Community shall contribute towards ensuring a high level of  human health protection by en-
couraging cooperation between the Member States  and,  if necessary,  lending support to their 
action. 
Prevention of  diseases 
Community action shall be directed towards the prevention of diseases,  in particular the major 
health  scourges,  including drug dependence,  by  promoting  research  into their causes  and 
transmission, as well as into health information and education. 
Health promotion in other Community policies 
Health protection requirements shall form a constituent part of the Community's other policies. 
Paragraph 2 stresses two points: 
Coordination of  certain policies and programmes in  the health field between Member States 
Member  States shall, in liaison with the Commission, coordinate among themselves their policies 
and programmes in the areas  referred to in paragraph 1. 
The right of  the Commission to take initiatives to promote this coordination 
The Commission may, in close contact with the Member States, take any useful initiative to pro-
mote such coordination. 
Paragraph  3 goes two steps further: 
Cooperation with third countries 
The Community and the Member States shall foster cooperation with third countries. 
Cooperation with international organizations 
The Community and the Member States shall cooperate with international organizations in the 
sphere of public health. 
Finally paragraph  4 sets  out the two legal  means for achieving the objectives of this Article 
specifically excluding the harmonization of laws and regulations: 
Incentive measures 
In order to contribute to the achievement of  the objectives referred to in this Article, the Council: 
acting in accordance with the  procedure referred to in Article  189b,  after consulting the 
Economic and  Social Committee and the Committee of the Regions,  shall adopt incentive 
measures, excluding any harmonization of the laws and regulations of the Member States. 
Recommendations 
In order to contribute to the achievement of the objectives referred to in this Article, the Counci  I: 
acting by  qualified majority on a proposal  from the Commission, shall  adopt recommen-
dations. Public health in  Europe  15 
Thus, it is probable that the current Europe against AIDS programme will be in-
corporated into a larger programme aimed at communicable diseases in general, 
which is planned for the years 1995 to 2000. The programme currently includes 
seven  areas of activity: (1)  assessment of awareness and behaviour, (2) children 
and  the  young,  (3)  prevention  of  HIV transmission,  (4)  social  support  and 
counselling, (5) data collection, (6) combating discrimination, and (7) research 
and  international cooperation. 
2.  The selection of  projects, assessment of results 
The Europe against AIDS programme supports projects that fall within one of  the 
areas of activity and are consistent with its general framework. Like other Com-
munity activities, this programme funds projects that are of value to the Com-
munity as  a whole and thus builds networks of organizations that can  benefit 
from collaboration. Similarly, the programme supports innovative projects which 
could serve as models for other Member States, rather than duplication of work 
being carried out elsewhere. Thus, pilot projects are funded, whereas support for 
established services is not an objective. Various other criteria are used for funding 
decisions. Firstly, the clarity of  aims, suitability of  the methodology and expertise 
of the organizations involved are assessed.  The inclusion of an  evaluation pro-
cedure is also a positive factor. Secondly, to ensure that projects are entirely con-
sistent with the laws or policies of the Member State in which they are to be car-
ried  out,  projects  that  have  the  moral  and  financial  support of the  relevant 
(national, regional or local) statutory bodies are given priority. Thirdly, the pro-
grammetries to maintain a balance between the work in different Member States: 
projects from countries or areas where the existing organization and capabilities 
are weakest are favoured. Thus, proposals from Member States where the need 
is greatest and HIV/AIDS work least developed are given a higher priority so as 
to help minimize the gaps  in Europe-wide coverage. 
The Europe against AIDS programme has learned that it must adopt a proactive 
approach to funding projects and in a number of instances have activities of  Com-
munity-wide interest carried out under contract. For a variety of reasons,  many 
excellent projects may not themselves apply for European Commission support. 
The programme therefore tries to search for organizations or groups who have 
good ideas or the ability to run valuable projects and does not simply wait for 
them to apply. 16 
3. Areas of  activity 
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The Eurobarometer survey,  carried out in each of the Member States of the 
European Community, between April and May 1994, has shown that: 
75% of Europeans are concerned about AIDS; 
80% of Europeans would like more information about AIDS; 
81% of Europeans do not want to reduce the amount of money spent on AIDS 
research; 
90% of Europeans think it is important that the Community aims to meet its 
own needs for blood and blood products from blood donations from its own 
citizens. 
Attitudes, awareness and behaviour 
This area covers  the assessment of knowledge, attitudes and  behaviour of the 
general public and particular groups within the population. These target groups 
include marginalized groups and populations with high-risk lifestyles, or  who are 
exposed to high-risk environments. The findings of this type of analysis are then 
used to improve information and awareness-raising campaigns. The need and 
desirability of studies to increase the  information available at the Community 
level are assessed. Information campaigns aimed at the general public and target 
groups (such  as  homosexuals, minorities and  migrants) are studied so that the 
results and lessons learned can be applied across the Community and to ensure 
that different organizations in different Member States are not working at cross 
purposes.  By distributing know-how and  lessons  learned, the European  Com-
munity  contributes  to  the  success  of projects  in  the  field  of awareness  of 
HIV/AIDS.  Similarly,  developments  in  methodology for  monitoring changes 
in  the knowledge, attitudes and  behaviour and  the impact of prevention pro-
grammes in Member States are made available throughout the European Com-
munity. Coordination and links are established between campaigns in Member 
States.  An  awareness  of the  problems that the  epidemic causes,  both  to  in-
dividuals and society,  is promoted. Experience is exchanged between those in-
volved in different response mechanisms such as telephone helplines and infor-
mation centres: the European Commission helps ensure that such  services are 
the best possible, give accurate information and preserve confidentiality. 
The Europe against AIDS programme has supported a project aimed at improv-
ing  methods  for  monitoring  understanding,  behaviour  and  attitudes  by 
developing standardized indicators (factors that can  be measured), and in-
tegrating them  into a coherent  system.  Furthermore,  the  programme  has 
organized a seminar to discuss the various different methods used in Member 
States  to assess  the impact of prevention  strategies  on the understanding, 
attitudes and behaviour of  the public and target groups. This may lead to the 
establishment of a European  network of research  workers and government 
officials involved in the assessment of preventive strategies. Public health in  Europe  17 
-----------------------------------------
Children and young people 
Children  and  young  people are  a key  target  group for preventive  measures. 
However, education and information must be appropriate for their maturity and 
cultural background. This area of activity therefore addresses HIV/AIDS educa-
tion in schools and the integration of this topic into more general sex and health 
education. Thus, programmes in different Member States designed for the young, 
whether in  schools or other formal  or informal educational  settings  (such  as 
social clubs), are exchanged and compared. Pilot educational projects address-
ing HIV/AIDS, including those specifically for minority groups, are encouraged 
and  appropriate educational materials are developed. 
The programme has funded two model projects for the education of young 
people by their peers. The first involves training young workers using theatre, 
visual  arts  and  music to communicate messages  about sexual  health  and 
education. The project takes the form of  video-cassettes, avai I  able through  out 
most of the Community, aimed at people involved in training and education. 
The  second  is  the  establishment of diverse  programmes  of sexual  health 
education in schools, colleges and other structures involving the young from 
more than one Member State (language schools for example). 
The  'AIDS  and  Youth'  European  information  centre  for  collaboration  on 
HIV/AIDS prevention among the youth of the Community has been funded. 
Prevention of  HIV transmission in particular situations 
Certain groups within the population and activities are associated with a high risk 
of HIV/AIDS transmission, or particular problems. The Europe against AIDS pro-
gramme therefore places special emphasis on  actions targeted at these groups 
and activities. They include, for example, travel, prisons, intravenous drug users 
IVDUs and the particular problems faced  by women. 
The efforts to ensure the use of  condoms as barriers to the transmission of HIV 
would be largely wasted if the condoms used were not effective as such. Fur-
thermore, these efforts would also be heavily undermined if  consumers believ-
1 
ed  that condoms did not provide adequate protection. The European Com-
munity therefore decided that it was  important to establish stringent quality 
standards for condoms on the market to ensure safety and maintain public con-
I  fidence,  and  also  to  make  high-quality condoms available throughout the 
Community.lnjune 1993, the Council of  Ministers of  the European Communi-
ty adopted a Directive on the quality of medical devices, including condoms. 
To obtain the CE  label, which allows unrestricted marketing throughout the 
European Community, condoms will be  subject to strict testing and quality 
control procedures. The details of the testing procedures are currently being 
finalized by the European Standards Committee. 18  A world with HIV/AIDS: The European Community response 
The movement of people is associated with the risk of  a rapid geographical spread 
of HIV/AIDS. However, trying to reduce this problem by restricting the right to 
travel  is  unacceptable and  also  ineffective. The programme therefore supports 
studies and exchanges of information and  experience on problems associated 
with tourism and travel  in the Community and to and from other countries out-
side the Community. 
Youth and tourism 
In Europe, summer knows no borders, or almost. Every year, millions of  young 
Europeans travel around the continent far-removed from everyday constraints, 
open to meeting new people. In this context, a common AIDS prevention cam-
paign is  increasingly being seen  as  a necessity.  In  the summer of 1994, 20 
countries are participating in such a campaign with a common poster and a 
multilingual AIDS prevention 'passport'; several million such passports will be 
distributed by a variety of non-governmental organizations NGOs. 
The countries of  Central and Eastern Europe are experiencing a rapid increase 
in prostitution, particularly near the borders with the Community. Many of  the 
clients are citizens of European Community States travelling across the fron-
tier. The Europe against AIDS programme therefore supports a project aimed 
at developing preventive actions in the areas of Eastern Europe bordering the 
Community, which present a major risk of spreading the epidemic on both 
sides of the borders. 
The Europe  an Commission has supported the establishment of  an information 
centre for immigrant groups, in particular for those originating from Asia, or 
who are Muslims. The differing cultural backgrounds, and in some cases  in-
tegration problems, raise particular problems for HIV/AIDS prevention in these 
groups. The centre supplies information, support and awareness activities for 
these groups in Europe in a culturally sensitive way. Similarly, the European 
Commission contributes to international activities designed to reach migrants 
living in Europe.  All  these  activities take  careful  account of cultural  sen-
sitivities and barriers to optimize communication between cultures. 
Prisons present particular problems of  transmission of the HIV virus; the recogni-
tion of this problem and the measures taken have been widely disparate. Current 
procedures for dealing with HIV/AIDS in prisons are examined and compared, 
and the European Commission facilitates the exchange of practical experiences 
on issues such as the availability of needles or cleaning material for prisoners who 
are IVDUs and condoms in prison. 
Intravenous drug users are a key group and in some Member States make up the 
largest  number of HIV/AIDS  cases.  It  is  therefore  important to evaluate  the Public health in  Europe  19 
knowledge, attitudes and behaviour of IVDUs as concerns HIV/AIDS, and then 
consequently adapt prevention strategies. The projects supported therefore in-
volve sharing experience on methods of supplying safe injecting equipment and 
assessing  the  potential  of  methadone-replacement  programmes  and  other 
measures to combat drug abuse for reducing the transmission of HIV/AIDS. 
A pilot project was run to prevent HIV infection among IVDUs. The project 
involved using ex-IVDUs to contact and  educate IVDUs in safer practices. 
Similarly, a second project was run to inform IVDUs who move within the 
Community about the various different information and care services in dif-
ferent Member States, and to make these services more accessible. 
The HIV/AIDS epidemic does not have the same profile in the two sexes. Women 
form a small but increasing proportion of  the cases. Projects addressing the situa-
tion of women at risk of HIV infection, particularly commercial sex workers are 
supported, as this is an area that needs further work. Pilot projects for prevention 
and support are promoted. Similarly, the Europe against AIDS programme sup-
ports analysis and exchange of information about the transmission of HIV from 
mothers to their children. 
In contrast to women, homosexual and bisexual men have made up a dispropor-
tionately large number of HIV/AIDS cases. Although the number of cases in this 
group is still rising, it is a falling proportion of  the total. The European Community 
is  involved in continuing efforts to prevent new cases,  particularly among men 
who may not have been  reached  by previous preventive actions. Thus,  the ex-
change of information between Member States about methods of prevention for 
this group is  encouraged. 
Social support and counselling 
The Community is neither mandated nor appropriate to replace Member States 
and  NGOs in supplying the social and psychological support individuals with 
HIV/AIDS  require.  Nevertheless,  the  European  Commission  can  greatly con-
tribute by the preparation and dissemination of manuals, information bulletins 
providing up-to-date information on  prevention,  care and  therapy,  and  direc-
tories  of support  and  information  organizations.  Furthermore,  the  European 
Commission encourages such organizations, particularly the NGOs, and Com-
munity actions. The programme gives priority to the Member States where sup-
port and counselling organizations are the least developed. 
The situation of children with HIV/AIDS and the access of these children and their 
families to education, and social and psychological care  is an  important issue. 20  A world with HIV/AIDS: The European Community response 
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A European support network has been established for families and children 
affected by H IV/  AI OS. This network supplies information and allows coopera-
tion and exchanges between organizations working with affected families so 
as  better to identify their needs and develop appropriate policies. 
European Community Directory of  AIDS service organizations 
The Directory has been produced in recognition of  the crucial role that NGOs 
play in combating the epidemic; they share the same  goals of stopping the 
spread of HIV, supporting those affected by HIV and AIDS, and fighting the in-
justice and social harm created by AIDS. The Directory aims to be a resource 
for all concerned in the European Community, and to promote the develop-
ment of better links between all the NGOs involved. The Directory, which has 
sections for each  Member State and for the pan-European organizations, is 
available in the nine official languages of the European Community. 
A European manual has been produced entitled The individual's health-care 
manual as a support and guide for people with HIV/AIDS. It is the result of ex-
tensive collaboration between experts in the fields of  social and psychological 
support and health care for people with H IV/AIDS. It contains information rele-
vanttothedifferentcultural, social and medical environment of  each Member 
State. 
Collection of  data and epidemiology 
Accurate and  extensive epidemiological data are  vital  for planning strategies 
adapted to the problem. The European Commisson plays an important role in this 
area. The Europe against AIDS programme supports epidemiological studies and 
data collection in  Member States,  in  part through the European Centre for the 
Epidemiological Monitoring of  AIDS (Paris). The work of  this Centre is described 
below, as  it is also heavily implicated in research work. Other actions include 
the encouragement of epidemiological training for HIV/AIDS and related fields, 
and  building upon  links between the  institutions responsible in the Member 
States. There are also projects to analyse the circumstances of HIV-infected per-
sons who remain asymptomatic for long periods, and the role of other diseases 
associated with AIDS. To allow improved planning and policy-making, the Com-
mission  facilitates  exchanges  of  information  concerning  the  epidemic  and 
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The  costs  of the  HIV/AIDS epidemic are  both  social  and  economic. The 
characteri sties of  the epidemic are such that these costs are d iffi cu It to estimate 
and quantify. The European Commission therefore sponsored investigations 
of the methods for assessing the cost of the epidemic. Various issues were ex-
amined: the predictive and planning models used in the Members States, the 
possibility of developing a common approach for measuring the costs of the 
epidemic, and also exactly what approaches and methods are appropriate for 
assessing the impact of the epidemic on health expenditure and other social 
costs. 
·--------------------1 
Combating discrimination 
Discrimination of any kind against HIV/AIDS patients is vigorously opposed by 
the European Community. It is both morally indefensible and counterproductive 
for public health. There is, therefore, an active campaign to combat discrimina-
tion,  in  particular  by  monitoring the  implementation  of anti-discrimination 
policy as  laid out in the resolution of the Council of Ministers for Health of 22 
December 1989. Discrimination and the potential for discrimination, particular-
ly in the areas of employment, insurance, housing, education and health care, 
are analysed in different Member States, so that ways to overcome the problems 
can  be developed. 
The European Commission has commissioned a comparative analysis of the 
various legislation in the Member States of  the European Community  to assess 
the legal and ethical impact on HIV/AIDS considerations. It is to provide an 
accurate description of the current situation as concerns various issues, such 
as testing, confidentiality, patients' rights to health care and discrimination or 
restrictions on  people with  HIV/AIDS. The  results  and  conclusions of this 
analysis may lead in the future to the establishment of protective measures at 
Community level. 
'-----------------------------
Coordination between programmes 
A large number of  different groups within the European Community are involved 
directly or indirectly in the HIV/AIDS issue. The Europe against AIDS programme 
ensures  coordination  between the various  programmes  related  to  HIV/AIDS, 
especially those  concerning research  and  associated  with aid  to developing 
countries. In the field of public health, the Europe against AIDS programme en-
sures  coordination with the other vertical  programmes (drugs)  and horizontal 
programmes (health promotion, information, education and training). For exam-
ple, various projects may first be funded as a research project and subsequently 
receive support from the Europe against AIDS programme as  the fruits of the 
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in  close collaboration with other structures within the Community to ensure 
complementarity  and  maximum  Community  added-value,  and  avoid 
duplication. 
The European Community also works closely with international organizations. 
For example, the Europe against AIDS programme has co-financed various pro-
jects with the World Health Organization (WHO). 
8 - Other activities in Europe 
1.  Blood, blood products and medicinal products 
The HIV/AIDS epidemic has obviously had consequences for the use of a variety 
of products in the medical sector. Two groups can be identified. The first is pro-
ducts  that could  potentially be  contaminated  by  HIV,  and  therefore  lead  to 
patients being infected. This group includes blood and  components of blood 
used for transfusion, and other medicinal products derived from human blood. 
The  second  is  medicinal  products  which  may  be  of benefit to  people with 
HIV/AIDS. 
Human blood and products derived from human blood for medical purposes 
The issue of the safety of human blood and  its components and derivatives for 
medical use is not specific to HIV/AIDS, but also involves other viruses (for exam-
ple hepatitis and  herpes viruses).  Nevertheless,  the  problems associated  with 
HIV/AIDS have given a stimulus to considerations of this problem. From the late 
1980s the European Commission has examined the problems associated with the 
safety of these products. One of the main policies in this area is to achieve Euro-
pean Community self-sufficiency from voluntary unpaid donors. This minimizes 
the risk to patients, and is the most ethically satisfactory position. The European 
Commission is  keeping continuously under review the issue's  associated with 
self-sufficiency within the European Community. Member States are progressing 
towards self-sufficiency, and indeed this goal has been attained in several coun-
tries. Nevertheless, the European Commission considers that the situation can be 
further improved: better use of blood and blood products so as to reduce the de-
mand; increasing Community-wide awareness of the value of donating blood; 
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The European Commission is  currently examining the safety of the transfusion 
chain, from pre-donation through processing and  distribution to post-transfu-
sion. Various issues are being highlighted. They include the further harmoniza-
tion of selection of donors ami accreditation of blood centres. In particular, the 
European Commission is addressing problems associated with differences in the 
practices in the transfusion sy·;;tems  between the Member States. 
Medicinal products derived from blood are also potential sources of HIV infec-
tion. The European Community has  laid down detailed requirements for good 
manufacturing practice and marketing authorization, including suitable testing 
and control to ensure the quality, safety (including the absence of contamination 
by HIV and other viruses) and efficacy ofthese products. In addition, the methods 
of selection and  screening of blood donors recommended  by the Council of 
Europe and the WHO are compulsory for blood and plasma used for the produc-
tion of medicinal products. 
Medicinal products for AIDS patients 
Medicinal  products  for  the  treatment  of AIDS  are  given  the  status  of high 
technology products at the Community level, and are therefore examined by a 
European  Community  procedure  as  opposed  to  national  authorization  pro-
cedures which apply for most medicinal products. From the beginning of 1995, 
the European Medicines Evaluation Agency will examine these products and give 
an opinion leading to a binding Community decision. This will mean that new 
products which may be of benefit to people with HIV/AIDS will be rapidly and 
simultaneously available to all  patients in the Community, and with the same 
conditions for use.  To  accelerate worldwide availability of new products, the 
European  Community has  begun  a harmonization process with the USA and 
Japan. Thus the repetition of testing in different parts of  the world can be avoided 
with a corresponding saving in time and effort. 
Testing and testing kits 
A European Community Direc:ive on medical devices was adopted in June 1993. 
It covers the design, manufactL·re and marketing of various categories of medical 
device, including condoms. It also deals with diagnostic kits for testing whether 
an  individual is HIV-seropositive. The reliability and efficacy of these kits is ob-
viously important: better design and  quality control  in  manufacture results  in 
fewer false  results. The Directive addresses the issue and will ensure that only 
high-quality  testing  kits  will  be  available  on  the  market  in  the  European 
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2. Occupational health and exposure to biohazards 
The Single European Act has  led to the adoption by the European Community 
of a number of Directives for the protection of workers at the workplace. These 
include a Directive for the protection of workers from risks associated with ex-
posure to biological agents,  including HIV. Biological agents are classified on a 
scale of 1 to 4, according to the intrinsic risk associated with exposure, and HIV 
is classified as a category 3 agent. Thus, specific protection measures and health 
monitoring are required for all workers who may be exposed to HIV in the course 
of their work. 
C - Collaboration with Central and East  European countries 
The PHARE programme is the European Community programme of assistance 
to countries of Central and Eastern Europe. The activities are based on priorities 
established by the recipient countries. The programme includes two particular 
projects that have an impact on the HIV/AIDS epidemic. The PH ARE programme 
has  massively  funded  the  restructuring  of the  blood  transfusion  system  in 
Romania, the country in this region with the highest incidence of AIDS cases, 
largely due  to contamination ofthe blood transfusion chain. The programme sup-
plied technical expertise and financed the re-equipping of transfusion centres. 
The second project concerns the planning and implementation of  a family-plann-
ing programme in Bulgaria. This programme is currently starting and, due to the 
supply and encouragement to use condoms, should lead to reduced transmission 
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Personnel  policy 
The Occupational Health Service of  the European Commission is responsible 
for a workforce of  about 20 000 in Brussels (Belgium), Luxembourg, lspra (Ita-
ly) and more than  100 duty stations worldwide. The policy of the Occupa-
tional Health Service concerning HIV/AIDS in the workforce of the European 
Commission is the result of extensive collaboration with staff representatives 
and senior management. 
A concerted drive to inform the workforce started  in 1987.  During consulta-
tions, doctors give advice adapted to the individual's situation, particularly 
those travelling or posted to regions where the incidence of HIV/AIDS is high 
and answer any questions he or she may have. There have been major inform  a- · 
tion drives about every three years  involving the distribution of written ex-
planations of the disease, methods of prevention and precautions to be taken. 
Testing is available to everyone after discussion with his or her doctor during 
medical consultations. In  pre-recruitment medical examinations and during 
annual  check-ups,  an  HIV antibody screening  test  may  be  proposed.  No 
reason  is  required for refusal to be tested.  It is explained that asymptomatic 
HIV infection is not grounds for changes totheworkofthe individual or refusal 
of  an application. The results are subjectto strict medical confidentiality. More 
than 9outof10 people choose to be tested. HIV-positive individuals have been 
employed by the Commission. 
There are two main elements to the support offered to staff members who test 
positive. The first is immediate counselling from the doctor. This includes in-
formation about the health consequences and probable progression of the 
disease, and advice about general measures and precautions to be taken. Se-
cond, the patient is  referred to an  HIV/AIDS specialist and  multidisciplinary 
counselling facilities including psychologists and, if needed, psychiatrists to 
ensure that appropriate emotional support is  made available. The policy of 
non-discrimination is strictly applied. The Occupational Health Service treats 
people infected with HIV and individuals suffering from AIDS in the same way 
that it treats  patients suffering from any other serious disease.  Similarly, the 
European Community medical insurance and retirement schemes deal with 
such  persons  exactly  as  they  deal  with those  suffering from  other major 
diseases. V- Research 
A - Biomedical research within Member States 
1.  The political context 
The European Community involvement in research  has  several  aims.  First,  the 
data and analyses must be made available to policy-makers in all areas of Com-
munity activity. Second, research should contribute to the health and quality of 
life of citizens  in  the  Member States.  The  value  of research  concerning the 
HIV/AIDS epidemic to health policy is self-evident. The Medical Research  Divi-
sion of the European Commission was quick to recognize the potential problem 
of the epidemic.  It organized  a first  collaborative  meeting on  HIV between 
research virologists and the Research Division in September 1983, and the Euro-
pean Parliament's first discussions on the issue were similarly very early (1984). 
The Member States reacted later and did not give specific approval for action on 
HIV/AIDS in the European Community until 1987. 
The  fourth  medical  research  programme (1987  to  1991),  run  by  the Medical 
Research  Division  of  the  Directorate-General  for  Science,  Research  and 
Development, proposed three objectives in the field of HIV/AIDS: to produce a 
vaccine,  to develop a drug (or other therapy) to cure AIDS,  and to supply the 
epidemiological data and tools necessary for governments and European Com-
munity policy-makers to design a suitable health policy. 
These aims remain and the resulting activities have been continued and increas-
ed as part of the Biomed 1 programme (1991  to 1994). HIV/AIDS is a major com-
ponent of this programme but not the biggest. There are 39 networks involving 
458 different research  groups across  Europe studying HIV/AIDS as  part of the 
Biomed 1 programme.  Furthermore, a large number of these networks extend 
beyond  the  frontiers  of the  European  Community.  In  particular,  the  COST 
(Cooperation  on  Science  and  Technical  Research)  countries  (Austria, 
Switzerland,  Norway,  Sweden,  Finland,  Poland,  Hungary,  Czech  Republic, 
Slovakia and Turkey) participate in many of  the projects Here the role of  the Euro-
pean Community is notto conduct research itself, butto facilitate and coordinate. 
2. The selection of  projects 
Proposals from research workers or groups are screened for those projects which 
best merit funding. Research proposals are examined according to several criteria 
to select the most promising and those which fulfil the aims ofthe European Com-
mission. The first element in the selection procedure is anonymous peer review. 
Every  project  proposal  is  referred  anonymously  to  four  different  specialists 
chosen for their standing in that particular field of research. They each indicate 
the potential value of the proposal, according to its scientific content. Over 800 
different reviewers from all parts of the world have been used. The second step 
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support work that involves collaboration between groups in different European 
countries and where this collaboration will generate added-value. The collabora-
tion must bring benefits which would not be possible from work in a single coun-
try. Thirdly, the European Commission will only pay for this collaboration and 
the added-value it generates and not for the elements of the project which are 
national. In relative terms, the European Commission pays 5% and participating 
groups find the remaining 95% from within their own countries. Fourthly, the 
project must contribute to the aims of the biomedical research programme and 
the framework programme, which are to improve the quality of life and health 
of the citizens of the Member States. 
3.  The research programmes 
There  are  four  subprogrammes  being  conducted  in  the  field  of  HIV/AIDS 
research  as  part of Biomed 1. They are disease control and prevention, viro-im-
munology, clinical research, and vaccine development. 
Each of the activities backed by the European Community biomedical research 
programme is  one of two types. The first type is called concerted action (CA). 
These are collaborations between groups in different countries. The second type 
of activity is the establishment of centres of excellence or centralized facilities 
(CFs). 
Disease control and prevention 
It is  clear that surveillance of the HIV/AIDS epidemic in  Europe could be most 
efficiently managed from a single centralized facility. The European Centre for 
the Epidemiological Monitoring of AIDS was therefore established in Paris. 
Epidemiological data from all over Europe (87% of all AIDS cases  in  31  dif-
ferent countries) are collated by the European Centre for the Epidemiological 
Monitoring of AIDS and made available in a standardized format. A quarterly 
report  is  sent  to  each  of 600  correspondents  mostly  in  Europe  but also 
elsewhere in the world. The Centre has developed methods of trend analysis 
and prediction as part of its epidemiological expertise. The Centre also sup-
plies logistic support and a scientific secretariat for projects involved in the 
disease prevention and control programme. In addition, the Centre is a leading 
research group in the field of epidemiological AIDS research and is  heavily 
implicated in  numerous research projects. It has contributed to a much im-
proved understanding of  the scale and progression of  the epidemic both in the 
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Other projects in the disease prevention and control programme include con-
certed actions on perinatal transmission (see box below), mathematical modell-
ing, heterosexual transmission, preventive strategies, prevalence and risk factors 
among intravenous drug users (IVDUs), accidental exposure, infection in female 
prostitutes, HIV prevalence in sexually-transmitted-disease patients and sexual 
behaviour and risks of infection. Generally these projects are valuable to medical 
services and to administrative and financial planners. 
The concerted action (CA) on perinatal transmission of HIV was among the 
first projects in the world to investigate transmission of HIV from mother to 
child, the so-called 'vertical transmission'. The project continues to monitor 
transmission from mother to foetus and new-born child. By the end of 1992, 
1130 HIV-infected mothers and their children in 19 European centres were in-
cluded in the study. The numbers of vertically acquired cases of HIV infection 
in any one centre are too low to allow a significant statistical analysis. Thus 
collaboration  between  numerous  centres  has  allowed  a  much  better 
characterization of the  risk  factors  for  infection of children.  In  particular, 
premature birth (before 34 weeks) has been shown to be a risk factor and an 
additional risk of infection via breast-feeding was identified. This led to the 
WHO reviewing its guidelines on breast-feeding by HIV-infected mothers. The 
large  group  of  HIV-infected  children  followed  in  these  studies  will  be 
monitored to investigate the long-term prognosis for such cases. These studies 
may have consequences for obstetric and paediatric medicine. 
Vim-immunology 
The programme for viro-immunological research  encourages cooperation be-
tween  investigators  in  the  European  Community who work on  fundamental 
biological aspects of HIV and its effects on human biology, in particular on the 
immune systems and the mechanism by which HIV infection develops into AIDS. 
There are numerous different projects in this programme. However, one of the 
main achievements has been the establishment of  centralized facilities for testing 
in animals. Standardized animal models are necessary for investigating potential 
anti-HIV drugs and vaccines, and also for the study of the pathogenicity of the 
virus. 
Various animal models have been examined during work supported by the 
European Commission (including cats, chimpanzees and macaques). Maca-
ques may representthe best suited animal. They can be infected with their  own 
version of HIV: simian immunodeficiency virus (SIV).  Infection of macaques 
with SIV leads to the onset of some typical AIDS symptoms. This CA was in-
itiated in 1987 and now involves 10 primate research institutes in six European 
count  ric'>. 30  A world with HIV/AIDS: The  European Community response 
The European Commission has thus established a system for rigorous and stan-
dardized testing, and scientific research. Having identified suitable strains of 
HIVand SIV, various possible vaccines were tested. These studies showed that 
it  was possible to produce vaccines (inactivated or  split macaque-specific SIV 
preparations) which protected macaques against some SIV isolates. However, 
the protection was variable and the mechanism remains unclear. 
Obviously, one of the thrusts of research  is to develop an  antiviral agent which 
can cure HIV infection or, failing that, slow the development of AIDS in HIV-in-
fected people. On 1 July 1988, the European Commission therefore launched a 
CA for the design, synthesis and evaluation of new antiviral compounds against 
AIDS. This CA included a centralized facility for the screening of compounds. 
The project has been expanded and incorporated into the Biomed 1 programme. 
The European Commission screening facility now screens more than 10 000 
new compounds a year from all overthe world fortheir anti-HIV activity, and 
actively collaborates with more than 100 centres in 27 countries. Particularly 
prom  ising leads are actively pursued: the mechanisms of  action of  compounds 
which display antiviral activity are investigated and further compounds which 
may express similar and stronger activities are then produced or isolated and 
tested. 
A good understanding of the genetics of HIV would be valuable. There are two 
families of HIVand each contains different subtypes. Even within these subtypes, 
there is substantial variability. Genetic analysis can thus make a contribution, par-
ticularly in understanding the relationships between genetic determinants and 
pathology,  epidemiology, vaccine studies  and  mutant analysis.  A CF  for HIV 
genome  analysis  was  therefore  established  in  1992.  Methodology has  been 
developed for the rapid sequence determination of any HIV-1  isolate, and  the 
facility is herein a centre of expertise. It is now actively involved in numerous col-
laborative projects which require HIV sequence determination. Nevertheless, 
the demand is  massively in  excess of the capacity of the CF. 
In addition to these projects, the European Commission supports work on the im-
muno-pathophysiology of HIV,  immunogenetics,  HIV variability,  interactions 
between HIV and the cell membrane, the cell-mediated immune response and 
the neuropathology of AIDS. 
Clinical research 
The European network for the treatment of AIDS (ENTA)  was set up in 1989 as 
part of the clinical research programme to coordinate investigations in Member 
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ticular, the aims were to facilitate the completion of clinical trials, avoid duplica-
tion of effort, faci I  itate the collation of data,  and  promote exchange between 
groups. This has resulted in benefits in terms of know-how and experience being 
rapidly gained and diffused. For example, the analysis of the larger numbers of 
patients than would be available in a single country allows quicker and better 
substantiated conclusions to be  drawn about different forms of treatment and 
therapy.  The  projects  included  in  this  programme  include analyses  of anti-
pneumococcal  vaccine  and  particular  treatments  for  toxoplasmosis,  tuber-
culosis, and  Kaposi's sarcoma in AIDS patients. 
The  programme  includes  a  network for the  treatment of HIV and  AIDS  in 
children. There are several aspects to this project. However, all the elements are 
aimed at evaluating the benefits and any disadvantages of the various different 
therapies  for  HIV/AIDS  in  children.  In  particular,  the  drugs  zidovudine and 
dideoxyinosine (ddl), and various combination therapies are being analysed. 
Vaccine development 
The European vaccine against AIDS (EVA)  programme was  launched on 1 July 
1989. It provides high-quality and sophisticated laboratory reagents to research 
teams  across  Europe  and  encourages  collaboration  in  the  field  of vaccine 
development.  In  particular, this  programme has  made  large quantities of im-
munogens available and  provides a standardized model (macaques) for testing 
potential vaccine. 
The CF for the EVA programme is located at the NIBSC (National Institute for 
Biological Standards Control - Potters  Bar,  UK) which provides laboratory 
and administrative support and  houses a repository for the reagents.  These 
reagents  include experimental vaccine immunogens and fragments of HIV 
proteins. The reagents are available to laboratories participating in the EVA 
programme and other scientists. Because the development of  vaccines needs 
experimentation in well-characterized animal models, the EVA  programme 
therefore collaborates closely with the European Community concerted ac-
tion on SIV  in macaques. This collaboration has  made advances  in the ex-
perimental  model (SIV  in  macaques)  which allow some  optimism for the 
future. However, the programme remains at the preclinical stage of analysing 
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8 - Research  collaboration with developing countries 
1.  The political context 
The European Community also contributes to research projects involving coun-
tries outside Europe. HIV/AIDS work falls to the 'Life sciences and technologies 
for developing countries' programme. The characteristic of this programme is 
strong partnership with research institutions in developing countries. HIV/AIDS 
is  one of numerous health issues which pose serious problems in developing 
countries  and  a  budget  has  been  made  available  for  projects  concerning 
HIV/AIDS.  It  is  a condition which cannot be  cured  and  biomedical  research 
designed to develop therapy and vaccines is covered extensively by research in 
the Member States. The programme therefore supports projects which promise 
more immediate applications. The epidemic has been considered from the start 
as  sexually transmitted, and was included in the research  programme as  such. 
The EC-STD  programme is  not restricted to fundamental research, but aims to 
develop biomedical tools which are potentially valuable for the control of the 
STD  (sexually transmitted  disease)  including the  HIV/AIDS  epidemic.  Thus, 
epidemiology and investigations of modes of transmission are major elements in 
the programme. 
The European Community has consistently collaborated with the WHO Global 
programme on AIDS (GPA).  Its actions have thus  involved concertation of the 
research  agendas and  responding to the demands of Member States,  many of 
which are significant contributors to the WHO's programme of HIV/AIDS ac-
tivities, have well-structured research orientations. 
2.  The selection of  projects 
3.  The programmes 
To  be eligible, project proposals must involve groups in at  least two Member 
States  and one developing country. The European Commission only funds the 
collaboration but can fund all the costs associated with the interactions between 
the participating groups. HIV/AIDS projects are judged according to their poten-
tial value in  comparison with projects addressing other health  issues  such  as 
malaria and diarrhoeal diseases. The basis of the procedure for selection of pro-
jects is peer review. The process involves two panels of experts, one from Euro-
pean countries to assess the scientific merit and one from developing countries 
to assess  feasibility. A  European Commission advisory committee then  makes 
final recommendations. 
The programme of research  collaboration with developing countries concen-
trates on projects that may be of value to public health or medical practice in the Research  33 
shortterm. The European Commission funds investigations of  the interaction be-
tween tuberculosis and HIV/AIDS, an association which is frequent and a major 
burden on the health services in the developing world. The programme supports 
a variety of projects which assess the epidemiology of tuberculosis, the effects 
of tuberculosis on the immune system  of people with HIV/AIDS, and the value 
of tuberculosis prophylaxis for people with HIV/AIDS. 
The European Commission is funding a series of projects which analyse the 
characteristics and relatedness of strains of mycobacterium tuberculosis (the 
causative organism oftuberculosis) isolated from people also infected by HIV. 
Modern molecular genetic techniques are  used  to identify and  compare 
strains isolated from individuals in various geographical regions and at dif-
ferent stages of disease (reinfection, relapse and  reactivation). These studies 
will lead to a better understanding of the biology and epidemiology of tuber-
culosis  infection,  and  this  knowledge  may  help the design  of preventive 
strategies and improve clinical management of patients. 
The infrastructure and facilities in developing countries are often poor and the 
methods and techniques used in industrialized countries are often inappropriate. 
The programme has  identified methodological work designed to improve the 
methods and the use of biomedical tools available in the developing world as an 
important area of research. Similarly, the European Commission supports work 
on the methods required to integrate appropriate HIV/AIDS interventions into 
general  health services. 
Finally, HIV/AIDS is a sexually transmitted disease and the European Commis-
sion supports numerous research projects on this subject. Projects investigating 
what are the best and  most relevant methods to control STDs are funded. The 
European Commission promotes analyses of the value and methods to measure 
and assess the impact of projects, such that approaches can  be compared and 
planned rationally, rather than in a spontaneous and haphazard way. As no cure 
is  available, traditional methods of assessing  the outcome of interventions on 
purely medical criteria are inadequate. The European Commission encourages 
work to develop novel  methods, particularly in the field of social sciences, for 
assessing the overall  impact of interventions and actions. VI - Aid activities outside Europe 
A - The political context 
The scale and consequences of the HIV/AIDS epidemic are currently greatest in 
Africa  and  all  predictions  suggest  that  other developing  regions  will  suffer 
similarly. These regions are among the worst equipped to address the problems 
resulting from  the  epidemic.  In  contrast,  Europe contains a large part of the 
world's medical, technological and logistical expertise. The European Commis-
sion adopted the attitude as early as 1986 that Europe should contribute to action 
in the field of HIV/AIDS as a public health problem on a worldwide scale, and 
not just in  Europe.  In  mid-1987,  the Commission contacted  all ACP  (African, 
Caribbean and Pacific) States who were signatory to the second Lome Conven-
tion on European aid to developing countries and invited them to take part in an 
EC-ACP HIV/AIDS programme. Almost all the ACP countries responded and par-
ticipated in this unique initiative. The result of this initiative was the launch, in 
1987, of a programme entitled 'HIV/AIDS programme for developing countries' 
to be  managed  by  DG VIII  (Directorate-General for Development). This  pro-
gramme was extended to non-ACP countries in  1988. The programme rapidly 
became operational and it has already participated in more than 120 projects in 
over85 countries across the world. This programme was not intended as a perma-
nent structure, but as a first, rapid response. However, its good performance and 
the realization that the problems posed by the HIV/AIDS epidemic are both large-
scale, and long-term have resulted in the continuation of this collaborative pro-
gramme. The projects are planned and implemented in partnership with govern-
ments,  NGOs, and scientific institutes for example. Indeed, it is these partners 
which execute the projects, and the input of the European Community is finan-
cial, planning and know-how. 
B - The health context 
In developing countries, the most common mode of transmission of HIV/AIDS 
is sexual transmission. Furthermore, in the 1980s, various studies (including pro-
jects supported by the European Community) showed that people suffering from 
sexually transmitted diseases (STDs) other than HIV/AIDS are more likely to be 
infected by or transmit HIV. Thus, the control of STDs would contribute to the 
control of HIV/AIDS, as well as beil)g a desirable aim in its own right. Monitoring 
the incidence of STDs in a population also gives an indication of the likely future 
course of the HIV/AIDS epidemic, as many ofthe risk factors are common to both 
H IV/AI OS and other STDs. Similarly, many preventive actions are effective against 
both HIV/AIDS and other STDs. These various observations have led to the Euro-
pean Community programme of health aid to the developing world addressing 
reproductive tract infections (or RTI,  a term covering STDs  including HIV/AIDS 
and other infections of  the reproductive tract which are not sexually transmitted) 
as a single coherent field of activity. Thus the European Community has initiated 
and sponsored numerous activities in the developing world in which HIV/AIDS 
prevention is only one of the goals. 36 
C-Airns 
A world with HIV/AIDS: The European Community response 
The European Community programme of collaboration with developing coun-
tries in the area of HIV/AIDS work has now been running for seven years and has 
accumulated substantial experience. During this time, lessons have been learned 
from past activities and a coherent approach has  been developed to the com-
plicated  issues  involved.  Indeed  the  complexity of the  ramifications  of the 
HIV/AIDS problem have led to a precise theoretical framework of strategies and 
policy principles being established. The four strategies which have been  iden-
tified as priorities are: to minimize the spread of HIV/AIDS; to help the health sec-
tor to cope; to minimize the effects of the epidemic; and to develop know-how 
and the learning process. 
(1) Minimizing the spread of the epidemic while preventing discrimination 
The first objective is to prevent new infections. In much of the developing world, 
the major route of infection is sexual transmission. Thus, the aim is to promote 
measures which help to protect against HIV infection (e.g.  use and availability 
of  condoms, safer sexual behaviour) and sexual and reproductive education. This 
area also includes the management of STDs in general. Certain groups such  as 
adolescents, refugees and the poor are given special attention. Methodologies 
are  being developed  to  screen  certain  development projects  for  potentially 
negative  effects  on  the  HIV/AIDS  epidemic.  Specific  HIV/AIDS  regulations, 
legislation and charters are drafted to prevent discrimination against people with 
HIV/AIDS. This is reinforced by non-coercive education and encouraging govern-
ments to protect marginalized groups. 
The  European  Community planned  and  organized  a  project in  Kinshasa 
(Zaire) to make condoms and other STD services available to 1 200 commer-
cial sex workers. After two years, the use of  condoms by this group rose from 
0 to 60%. The consequences of this project included a drop in the annual 
incidence if HIV infection in the group from 18 to 3%, and a decline in the 
incidence of other STDs. 
(2)  Helping the health sector to cope 
The growing number of people with HIV-related symptoms is a heavy burden on 
health  services,  particularly  in  poorer countries.  The  European  Community 
therefore supports these health services in dealing with the problems they face, 
both for the management of HIV-infected people, and in their efforts to prevent 
the spread of the epidemic as well as the efforts in the field of STD  in general. 
This  involves,  for  example,  the  development  of  low-cost  care,  appropriate 
therapy,  and  inclusion of condoms,  relevant drugs  and  diagnostics  in  public 
health packages.  In particular, there is a major programme for safe blood provi-
sion. In the long term, the problems posed by HIV/AIDS must be addressed  in 
all health policy discussions and health sector reviews and  reforms. Aid activities outside Europe 
The Mozambique project is  a model of horizontal  integration of STD,  in-
cluding  HIV/AIDS,  activities  into  health  services.  The  country  presents 
numerous characteristics  which favour the spread  of HIV/AIDS and other 
STDs: poverty, civil war and large numbers of refugees leading to high-risk sex-
ual behaviour. STD control had received little attention before the HIV/AIDS 
epidemic. A pilot project was  initiated in 1988 in the capital city Maputo to 
support and improve the treatment and diagnosis of reproductive tract infec-
tions, both at local primary care level  and also at the level of the reference 
hospitals. Similarly, counselling was made available to STD patients and their 
partners. This strategy allowed patients to be treated in primary health-care 
centres, and so there was a corresponding reduction in referrals. The result was 
a better use of health-care resources. The other achievements of this project 
include the establishment of guidelines for the diagnosis and  treatment of 
STDs and counselling by the health-care provider, the creation of a panel of 
STD experts, an analysis of costs and financing the service. These lessons have 
since  been  applied  and  the  project  extended  to  other  provinces  in 
Mozambique. 
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(3) Minimizing the consequences of  HIV!AIDS on social and economic development 
The epidemic has large economic and social consequences. It is therefore impor-
tant to understand what the effects are,  and are likely to be, on social structure 
and on economies. Furthermore, various cooperation and development projects 
may have a negative impact on the HIV/AIDS epidemic, or necessitate considera-
tion  of  the  impact  of HIV/AIDS  on  the  project.  The  European  Community 
therefore  backs  appropriate  analyses  and  promotes  an  awareness  of issues 
related to HIV/AIDS among decision-makers. This encourages the adaption of 
programmes and  projects to address  the various  problems and  minimize the 
potential  negative  effects.  For  example,  special  support  is  made available  to 
orphans or to communities in which many young adults have HIV/AIDS, and thus 
there may be a relatively low proportion of productive individuals, and a large 
proportion of dependants. 
(4) The development of  know-how and objective analysis of  problems and interventions 
The European Community encourages a learning process so that lessons can be 
learned and consequences better understood and corrected as  necessary. This 
involves  improving  the  balance  between  biomedical  and  socio-economic 
research. The capacities of national and regional research bodies in developing 
countries should be strengthened. New findings should be rapidly applied asap-
propriate. Subsequent interventions can thereby be further improved and know-
how increased. 38  A world with HIV/AIDS: The European Community response 
The project in perinatal clinics in Nairobi·(Kenya) is a good example of  the way 
in which the programme analyses an existing situation and learns the lessons 
such that the performance of a health-care system can be improved. Thirteen 
clinics handling syphilis testing and the treatment of pregnant women were 
monitored for six months (see figure below). A total of 540 women attended 
but, for various reasons, blood samples were only collected from three out of 
five, and test results were available for just over half. 
Thus the system failed to screen almost half  the women. Of  the 11  women who 
were found to be suffering from syphilis, only one was adequately treated. It 
is  clear that although  health-care structures existed  they were inefficiently 
used.  The  European  Commission  helped  reorganize  the  procedures  and 
management of these health-care services. The result was that most women 
attending are now tested and most of  those who are suffering from syphilis are 
adequately treated.  Furthermore, the use of resources was enormously im-
proved and the cost of  preventing one case of  congen ita I syphilis fell from U  5  D 
730 to USD 57. 
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D - Policy guidelines 
The European Community considers it extremely important that all interventions 
in the programme of cooperation with developing countries in pursuit of these 
aims must respect six basic policy principles. In brief, these are adaptation to risk, 
gender sensitivity, learning, empowerment, integration and timing. 
(1) Adaptation to risk environment 
The environment in which individuals find themselves (socially, politically and 
culturally) has enormous consequences for the risk to which they are exposed. 
Furthermore, these factors can  have  large effects on the value of interventions 
aimed  at  reducing  the  spread  of the  epidemic.  Thus,  demographic,  socio-
economic and cultural considerations must be taken  into account when plan-
ning action. The action should be adapted and appropriately targeted to the par-
ticular risk groups present (for example commercial sex workers and their clients, 
truck drivers, military personnel, migrant labour, disadvantaged women or the 
young) and to their situation. 
(2) Gender sensitivity and specificity 
The characteristics of the epidemic are not the same among men and women. 
Interventions and analyses therefore have to be designed according to gender. 
Furthermore, for cultural, economic or social  reasons,  many women are  not 
always  in  a  position  to  make  informed  choices  about  protection  and  safe 
behaviour. Thus, the legal protection of  women and their economic, political and 
social empowerment can make a valuable contribution to minimizing  the spread 
of the HIV/AIDS epidemic. 
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The  graph  on  page  39  shows  some  of  the  differences  between  the 
characteristics of  STDs and STD treatment in male and female populations. For 
example, the incidence of STDs among women is lower, but four times more 
men receive adequate treatment and are cured. It  is clear that the interventions 
that would have the most effect are different for the two populations. For exam-
ple,  education  allowing  individuals  to  recognize  their  symptoms  and 
measures encouraging them to present themselves for health care will have a 
much greater  impact among women  (only  half the women with an  STD 
recognize that they have symptoms and only one in four present) than among 
men (nine out of ten men with an STD recognize the symptoms and five out 
of  six present). In contrast, the proportion of individuals presenting themselves 
who are adequately treated and cured is slightly higher among women than 
men. This illustrates the importance of gender specificity in interventions. 
(3) Social/earning and respect for human dignity 
Interventions based on strategies involving the coercion of individuals and com-
munities are counterproductive. This approach drives epidemics underground, 
where they are more difficult to control. The European Community therefore en-
courages  interventions focused  on  both  individuals and  societies themselves 
learning to minimize risks of infection in an atmosphere of tolerance, respect of 
the rights of the individual and personal dignity. This involves government-led at-
titudes  and  legislation  protecting and  supporting  particular communities or 
groups from coercion and discrimination associated with STDs and  HIV/AIDS. 
(4) Empowerment and responsibility 
Many types of interventions in the field of HIV/AIDS cannot be satisfactorily im-
posed  and  administered  from  above  because  they require  individuals taking 
responsibility  for  their actions  and  making  appropriate  choices  about their 
behaviour. The mobilization and motivation of communities and individuals is 
therefore crucial. Nevertheless, organizations and governments can greatly con-
tribute to these types of project by removing barriers, and giving sufficient power 
and responsibility to the groups or individuals concerned to allow them to make 
their own choices to minimize risk and  adapt their behaviour.  The  European 
Community therefore has a policy of supporting changes that promote the rights 
of the individual (particularly in the field of property laws, women's status, etc.), 
and  strengthen  local communities and the representation of minority groups. Aid activities outside Europe  41 
(5) Integration into wider frameworks 
The integration of HIV/AIDS-related issues and actions into a variety of sectors 
contributes to action against the HIV/AIDS epidemic. Allocating different tasks 
to appropriate people or organizations  leads  to  improved  overall  cost-effec-
tiveness.  Numerous  different  sectors  can  contribute  to  m1n1m1z1ng 
HIV/AIDS-related  problems.  Thus,  national  HIV/AIDS  policies  are  valuable 
because they can lead to the incorporation of HIV/AIDS issues into, for example, 
education, health, aid and development policies and programmes, and facilitate 
collective action by diverse groups. Similarly, NGOs, community groups and the 
private sector can  all contribute, and for best effect, the actions taken by these 
diverse groups should be complementary. 
(6) Adaptation to the stage of the epidemic and rapidity of response 
The  HIV/AIDS epidemic is  at different stages  in different parts  of the world. 
Similarly, the local response depends on the characteristics of the local political, 
economic and cultural conditions and is thus very variable. Furthermore, there 
are often delays in establishing appropriate interventions due to,  for example, 
political denial or administrative inertia. The  European  Community therefore 
helps adapt responses to the stage and characteristics ofthe epidemic locally and 
encourages governments and administrations to work efficiently and objectively. 
In  particular, the European Community helps the implementation of interven-
tions and actions appropriate to the stage of the epidemic. VII - Conclusions - Strategies for the future 
The HIV/AIDS epidemic continues to spread. Societies are going to have to ac-
cept that the epidemic will be  a growing health problem for the foreseeable 
future.  However,  public  opinion  demands  action  and  populations  and  in-
dividuals want protection. 
Novaccineorcurecan be expected intheshortterm, which means that strategies 
other than classical biomedical approaches to controlling the epidemic have to 
be used. These observations underlie the policies and actions of the European 
Community. Obviously, research work  towards the goals of  a vaccine and therapy 
must continue to be encouraged. Modern scientific techniques are powerful and 
it seems unlikely that the wealth of data being generated will not eventually lead 
to medical applications. The epidemic has,  however, shown the need for new 
types of research  in the area where health and social sciences meet. Improved 
understanding of  the behaviour of  populations and individuals, and better assess-
ment of the effects of interventions would help planners and policy-makers op-
timize subsequent activities. Indeed, the European Community has largely based 
its action on activities in this area, and will continue to do so.  Various types of 
actions have already proved to be of  value, and such actions should be expanded 
and implemented more widely. All interventions should be rigorously assessed, 
and the consequences analysed, such that they can  be continuously improved 
and adapted. 
Its experience in this field has led the European Community to place HIV/AIDS 
policies in a broader context: they make up part of a larger picture of the drive 
to the improved health and well-being of individuals and communities. Govern-
ments, and other bodies with power, have a responsibility to create and maintain 
the conditions in which the spread can be minimized. However, individuals also 
have  responsibilities.  Transmission  is  dependent on the  behaviour of the  in-
dividual, so  individual behaviour is the best target for preventing the spread of 
the epidemic.  It appears  obvious to conclude that individuals should  simply 
change their behaviour. A more profound analysis suggests that one of  the impor-
tant roles of government and similar organizations is to make this possible. Peo-
ple who are not informed, do not have free choice about their lifestyle, or do not 
have access to appropriate material or  emotional supports are unlikely to change. 
It is these problems that the European Community will continue to try to tackle. European Commission 
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